Host: Joshua Brody, MD, Icahn School of Medicine at Mount Sinai Guest: Jeremy Abramson, MD, MMSC, Harvard Medical School This episode is supported by an educational grant from Genentech. Episode Summary: Until recently, patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who couldn't have a transplant had no curative options. Today, nearly every patient in the second line can be treated with curative intent. Dr. Josh Brody and Dr. Jeremy Abramson walk through the options: CAR T-cell therapy, bispecific antibodies, antibody-drug conjugates (ADCs), and combinations of these. They cover how to choose the optimal therapy for transplant-ineligible patients, especially when CAR T is not an option or if the disease is progressing rapidly. They also discuss the role of MRD testing in monitoring treatment response, long-term infection risk with bispecific antibodies, and practical tips for coordination of care between academic centers and community oncologists. HOST: Joshua Brody, MD Director, Lymphoma Immunotherapy Program Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine @JoshuaBrodyMD LinkedIn GUEST: Jeremy Abramson, MD, MMSC Director, Jon and Jo Ann Hagler Center for Lymphoma Professor of Medicine, Harvard Medical School LinkedIn Topics Covered: Second-line options for transplant-ineligible relapsed/refractory DLBCLCAR T-cell therapy: curative potential and barriers to accessBispecific antibody regimens: glofitamab-GemOx (STARGLO), epcoritamab-GemOx, and mosunetuzumab-polatuzumab (SUNMO)ADC regimen: Polatuzumab-R-GemOx (POLARGO)Bridging therapy before CAR T-cell therapy: low-dose radiation, systemic options, and investigational glofitamab-GemOx regimenMinimal residual disease (MRD) testing and the ALPHA3 trialCombining ADCs and bispecific antibodies: loncastuximab tesirine, glofitamab and mosunetuzumab or polatuzumab (LOTIS-7 trial)Toxicities: CRS, hypogammaglobulinemia, and infection riskCoordinating care between academic centers and community cancer centersRelated Resources: Slides from SOHO Breakthroughs in Blood Cancers, Aggressive B-cell lymphomas, Julie Vose, MDWhat is the 2025 treatment landscape in DLBCL? Jason Westin, MDWhat are the areas of unmet needs in large cell lymphoma? Loretta Nastoupil, MDConnect With Us: Website: HomeNewsletter: SOHO InsiderYouTubeFacebookX (Twitter)LinkedInInstagramThe views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Society of Hematologic Oncology.
